TABLE 1.
BASELINE CHARACTERISTICS OF SYMPTOMATIC VS ASYMPTOMATIC PATIENTS WITH HOLLENHORST PLAQUES
| BASELINE CHARACTERISTICS |
SYMPTOMATIC (N=60) |
ASYMPTOMATIC (N=177) |
P VALUE (FISHER EXACT TEST) |
|---|---|---|---|
| Age (years) | 70.7 ± 9.5 | 70.9 ± 9.8 | .810 |
| Gender: female/male (%) | 21.7 / 78.3 | 39.0 / 61.0 | .018* |
| BMI (kg/m2) | 29.5 ± 5.0 | 28.7 ± 7.8 | .359 |
| Hypertension (%) | 56.7 | 69.5 | .083 |
| Diabetes mellitus (%) | 18.3 | 26.6 | .227 |
| Hyperlipidemia (%) | 58.3 | 55.9 | .766 |
| Current tobacco use (%) | 18.3 | 14.1 | .414 |
| Any tobacco use (%) | 74.6 | 61.6 | .084 |
| Coronary artery disease (%) | 53.3 | 40.1 | .097 |
| Cerebrovascular disease (%) | 23.3 | 23.7 | 1.000 |
| Peripheral vascular disease (%) | 16.7 | 19.8 | .705 |
| Significant carotid disease (%) | 6.7 | 12.5 | .338 |
| Current aspirin use (%) | 43.3 | 62.7 | .010* |
| Current clopidogrel use (%) | 1.7 | 5.1 | .459 |
| Current warfarin use (%) | 15.0 | 8.5 | .213 |
| Current beta blocker use (%) | 33.3 | 31.6 | .873 |
| Current ACE/ARB use (%) | 38.3 | 33.3 | .531 |
| Current statin use (%) | 33.3 | 36.7 | .756 |
ACE, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; BMI, body mass index.
*
Statistically significant (P<.05).